TELA Bio, Inc.

TELA

$0.75

-4.92%

2026-09-02 16:00:00 EDT-$0.04

Healthcare

Medical - Devices

NASDAQ

Active Trading

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation ...

Price Action of TELA

$0.75

-4.92%-$0.04

High—

Low—

52W High-56.4%

Rel. vol—

Interval

Range4.2h

Volume—SMA5SMA10

—

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company headquartered in Malvern, Pennsylvania, founded in 2012. The company focuses on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy. TELA's primary product portfolio includes OviTex Reinforced Tissue Matrix products for ...TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company headquartered in Malvern, Pennsylvania, founded in 2012. The company focuses on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy. TELA's primary product portfolio includes OviTex Reinforced Tissue Matrix products for hernia repair and abdominal wall reconstruction, as well as OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. Additionally, the company offers OviTex for Laparoscopic and Robotic Procedures, utilizing a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber. These products are marketed through a direct sales force primarily in the United States. TELA Bio went public in November 2019 and is listed on NASDAQ under the ticker symbol TELA. As of the latest data, the company has 218 full-time employees and is led by CEO Antony Koblish, who co-founded the company. Financially, TELA Bio is in a growth phase, with revenue per share of $1.392 but negative net income per share of -$0.717, reflecting its ongoing investment in commercialization and R&D. The company's gross profit margin is approximately 67.8%, indicating strong product economics, but operating expenses, particularly sales and administrative costs (98.4% of revenue), have led to negative operating margins. The company's market capitalization is around $35 million, with a stock price of $0.79 as of the latest data. Despite current losses, TELA Bio focuses on providing cost-effective surgical solutions that leverage natural healing, aiming to improve patient outcomes while delivering economic value to healthcare systems. With a strong emphasis on innovation and clinical outcomes, TELA Bio continues to expand its product offerings and market presence in the soft-tissue reconstruction space.ExpandCollapse

Founded

2012

Employees

218

CEO

Heather Getz

Full Name

TELA Bio, Inc.

Sector

Healthcare

Industry

Medical - Devices

ROE

1248.13%

Market Cap

$0.03B

Current Ratio

2.99

WACC

10.02%

ROIC

-83.60%

Contact Information

https://www.telabio.com

484 320 2930

1 Great Valley Parkway, Malvern, PA 19355

Key Metrics of TELA

Snapshot

Latest / TTM · 6 periods

Market Cap

$33.66M

ROCE

-81.9%

EV / EBITDA

-1.85x

-28.7% YoY

FCF Yield

-90.5%

-38.7% YoY

Cash Conversion Cycle

160.0d

Current Ratio

2.99

Quick take

TTM —

Positive CCC

Financial Highlights of TELA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

67.8%

Net Margin

-51.5%

P/E Ratio

-1.01x

n/a

Debt / Equity

-3.57

n/a

Current Ratio

2.99

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of TELA

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.15 · Revenue $20.04M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.13 · Revenue $21.24M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.69 · Revenue $79.64M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.11 · Revenue $20.78M · 1 analysts

Recent history

Aug 11, 2026
Q2 FY2026 · Results reported
EPS $-0.20 · Revenue $19.29M
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-0.21 · Revenue $19.06M
View filing
Mar 25, 2026
FY2025 · Annual results
EPS $-0.83 · Revenue $80.28M
View filing
Nov 14, 2025
Q3 FY2025 · Results reported
EPS $-0.19 · Revenue $20.69M
View filing
Aug 11, 2025
Q2 FY2025 · Results reported
EPS $-0.22 · Revenue $20.20M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $-0.25 · Revenue $18.52M
View filing

Financial Statements of TELA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$80.3M	+15.8%	+1.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-38.8M	-2.6%	+8.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+67.7%	+0.9%	+10.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-42.0%	+14.6%	+12.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-48.4%	+11.4%	+9.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-28.7M	+32.7%	+16.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-35.7%	+41.9%	+17.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	881.6%	+482.6%	+67.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.20x	-16.0%	-17.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$81.4M	-6.8%	-14.5%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.83 vs -0.82	-1.5%	-0.20 vs -0.17	-15.1%
Revenue Surprise	$80.3M vs $80.4M	-0.2%	$19.3M vs $20.0M	-3.6%

Insider Transactions of TELA

Acquisitions (A)

Since Jun 9, 2026

Disposals (D)

Since Jun 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 17, 2026	Getz Heather C	director, officer: Chief Executive Officer	Common Stock	A	12,500	$0.66
Aug 14, 2026	Getz Heather C	director, officer: Chief Executive Officer	Common Stock	A	15,000	$0.70
Aug 3, 2026	Getz Heather C	director, officer: Chief Executive Officer	Stock Option (Right to Buy)	A	1,365,000	$0.74
Aug 3, 2026	Getz Heather C	director, officer: Chief Executive Officer	Stock Option (Right to Buy)	A	1,005,000	$0.90
Aug 3, 2026	Getz Heather C	director, officer: Chief Executive Officer	Common Stock	A	500,000	—

Earnings Call Transcript of TELA

4 transcript segments

Q2 2026

OperatorOperatorSentiment 0.0

Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. Following the prepared remarks, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Louisa Smith.

Louisa SmithHead of Investor RelationsSentiment 0.0

Thank you, Lisa, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the second quarter ended 06/30/2026. A copy of the press release is available on the company's website. Joining me on today's call are Heather Goetz, Chief Executive Officer; Jeffrey Blizard, President; Roberto E. Cuca, Chief Financial Officer; and Jim Hagen, Senior Vice President of Strategic Operations and Marketing. Before we begin, I would like to remind you that during the conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. With that, I will now turn the call over to Joe Capper.

Joe CapperBoard RepresentativeSentiment 0.6

Thank you, Louisa. Good afternoon, and thank you for joining TELA Bio's second quarter 2026 earnings call. I will start the call with a few comments about the important leadership change announced last week naming Heather Goetz as the new Chief Executive Officer and director of TELA Bio. Then I will turn the call over to the management team for an update on the business. Heather brings a proven track record of driving operational excellence, leading organizations through complex business and financial transformations, and creating long-term value. We are confident that under Heather's leadership, TELA Bio will build on its strong foundation, expand its impact for patients and surgeons, and deliver value for our shareholders and employees. On behalf of the Board, we also want to extend our sincere gratitude to Antony Koblish for his vision, leadership, and entrepreneurial spirit in founding TELA Bio and guiding the company through its early growth stage. Tony's commitment to innovation led to the development of OviTex, and helped establish TELA Bio as a leader in soft tissue reconstruction. We are deeply appreciative of his many contributions and wish him continued success in his future endeavors. I will now turn the call over to Heather.

Heather GoetzChief Executive OfficerSentiment 0.5

Thank you, Joe. Good afternoon, everyone. Let me start by extending my gratitude, especially to our team for the warm welcome. I am honored to join TELA Bio at such an exciting …

Leadership Team of TELA

13 executives

Name	Title	Compensation	Gender	Year Born	Status
Antony Koblish	Co-founder, Chief Executive Officer & Director	USD 968,595	Male	1966	Active
Jeffrey Blizard	President	USD 751,444	Male	1969	Active
Roberto E. Cuca	CFO, Corporate Secretary & COO	USD 652,875	Male	1968	Active
Paul Talmo	Chief Technology Officer	USD 580,554	Male	1967	Active
Heather C. Getz	CEO & Director	—	Female	1975	Active
Jennifer Lou Armstrong	Senior Vice President of Human Resources	—	Female	1970	Active
Megan Smeykal	Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer	—	Female	1976	Active
Howard N. Langstein	Chief Medical Officer	—	—	1959	Active
Jim Hagen	Senior VP of Strategic Commercial Operations & Marketing	—	Male	—	Active
Michael Leonard	Senior Vice President of Technical Operations	—	Male	—	Active
D. Taylor Ocasio	General Counsel & Corporate Secretary	—	Male	—	Active
Louisa Smith	Investor Relations Contact Officer	—	—	—	Active
Gregory A. Firestone	Chief Business Officer	—	Male	1959	Active

Recent News of TELA

Seeking Alpha8/11/2026Neutral

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

Zacks Investment Research8/10/2026Neutral

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.

GlobeNewsWire8/5/2026Neutral

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company's newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the “Standard Options”) and (ii) premium-priced stock options to purchase 1,005,000 shares of common stock (the “Premium-Options”). Additionally, the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 95,500 shares of its common stock to 11 newly-hired employees, with a grant date of August 4, 2026. The stock options and the restricted stock units discussed above were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Ms. Getz's and each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

GlobeNewsWire8/4/2026Neutral

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.

GlobeNewsWire7/29/2026Neutral

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference.

Historical Employee Count of TELA

Current

218

Change

+4.31%

Minimum

123

Maximum

227

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	218	10-K	Mar 25, 2026	View
Dec 31, 2024	209	10-K	Mar 21, 2025	View
Dec 31, 2023	227	10-K	Mar 22, 2024	View
Dec 31, 2022	173	10-K	Mar 23, 2023	View
Dec 31, 2021	123	10-K	Mar 23, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

TELA Bio, Inc.